Skip to content

Hydrogen-Rich Water as an Adjuvant Therapy for Obesity:one exploratory clinical study

Hydrogen-Rich Water as an Adjuvant Therapy for Obesity:one exploratory clinical study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103593
Enrollment
Unknown
Registered
2025-05-30
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Hydrogen-rich water group :The hydrogen-rich water group consumed 330 ml of hydrogen-rich water after breakfast, lunch, and dinner each day.
Purified water group:The purified water group consumed 330 ml of purified water after breakfast, lunch, and dinner each day.

Sponsors

Tai'an Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Reference: Based on the 2021 Expert Consensus on Body Weight Management Procedures for Overweight/Obese Populations issued by the Health Management Branch of the Chinese Medical Association: Overweight: 24 kg/m^2 = 28 kg/m^2 Central obesity (adults): Waist circumference = 90 cm (male) or = 85 cm (female). Inclusion Criteria: Meeting the diagnostic criteria for overweight or obesity; Aged 16–65 years; No concurrent use of medications that may affect body weight; Voluntary participation with signed informed consent.

Exclusion criteria

Exclusion criteria: Exclusion Criteria:Secondary obesity caused by:Hypothalamic disorders;Endocrine diseases (e.g., hypercortisolism, hypothyroidism, insulinoma);Medication-induced weight gain;Pregnancy, lactation, or women planning pregnancy within 6 months;Severe primary diseases of major organs (heart, liver, kidney);Coexisting severe conditions:Coagulation disorders;Infectious diseases;Malignancies;Liver cirrhosis;Any weight-loss medication or treatment within 3 months prior to enrollment, or >5% body weight reduction during this period;Inability to comply with treatment and follow-up protocols

Design outcomes

Primary

MeasureTime frame
body weight;waist circumference;body fat percentage;

Secondary

MeasureTime frame
blood glucose;blood lipids;blood insulin ;uric Acid;gut microbiota;

Countries

China

Contacts

Public ContactZhang Hanbing

Tai'an Central Hospital

zhanghanbing271413@126.com+86 150 6417 3082

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026